Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 501

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 501
---
15)           |     | $          | 3,328,500 |     | $            |         — |

Related party transactions

Related party transactions consisted of the following for the six months ended June 30, 2025 and 2024:

| Interest expenses (Note 15)      |     | For the six months 
 ended June 30,     
 2025               
 (Unaudited)        |        |     |        2024 
 (Unaudited) |
|:---------------------------------|:----|:-------------------|-------:|:----|------------:|
| – Jurchen Investment Corporation |     | $                  | 90,000 |     |      90,000 |

Note a: On August 13, 2019, Aptorum Therapeutics Limited (“ATL”), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited, a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $ million in line of credit

F-45 APTORUM GROUP LIMITED NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Stated in U.S. Dollars) 11. RELATED PARTY BALANCES AND TRANSACTIONS (cont.) debt financing. Both line of credits have originally matured on August 12, 2022. ATL and Aeneas Group Limited has mutually agreed to extend the line of credit arrangement further 3 yearsto August 12, 2024. The interest on the outstanding principal indebtedness is at the rate of 8% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of the date of this unaudited condensed consolidated financial statements, the undrawn line of credit facility is $ 12million. Note b:On January 13, 2022, ATL entered a line of credit facility with Libra Sciences Limited to provide up to a total $ 1million line of credit for its daily operation. The line of credit is originally matured on January 12, 2023, and is extended for additional 3 years. The interest on the outstanding principal indebtedness is at the rate of 10% per annum. ATL and Libra Science Limited mutually agreed to terminate the line of credit agreement